Central memory CD8+ T lymphocytes mediate lung allograft acceptance

Journal of Clinical Investigation

Volumn 124, Issue 3, 2014, Pages 1130-1143

  Krupnick, Alexander Sasha ^a   Lin, Xue ^a   Li, Wenjun ^a   Higashikubo, Ryuiji ^a   Zinselmeyer, Bernd H ^a   Hartzler, Hollyce ^a   Toth, Kelsey ^a   Ritter, Jon H ^b   Berezin, Mikhail Y ^c   Wang, Steven T ^c   Miller, Mark J ^a   Gelman, Andrew E ^a   Kreisel, Daniel ^a  

^a WASHINGTON UNIVERSITY   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR7; GAMMA INTERFERON; HERMES ANTIGEN; L SELECTIN; NITRIC OXIDE;

ALLOTRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ARTICLE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; IMMUNE RESPONSE; LUNG TRANSPLANTATION; MEMORY T LYMPHOCYTE; MOUSE; MULTIPHOTON MICROSCOPY; MURINE MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SYNAPSE;

ALLOGRAFTS; ANIMALS; ANTIGEN-PRESENTING CELLS; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; COCULTURE TECHNIQUES; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; LUNG; LUNG TRANSPLANTATION; MICE; MICE, INBRED BALB C; MICE, INBRED CBA; MICE, NUDE; NITRIC OXIDE; RECEPTORS, CCR7;

EID: 84896786817     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI71359     Document Type: Article

References (98)

1. Serraino D, et al. Risk of cancer following immunosuppression in organ transplant recipients and in HIV-positive individuals in southern Europe. Eur J Cancer. 2007;43(14):2117-2123.
2. Cervera C, Linares L, Bou G, Moreno A. Multidrugresistant bacterial infection in solid organ transplant recipients. Enferm Infecc Microbiol Clin. 2012; 30(suppl 2):40-48.
3. Larsen CP, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature. 1996;381(6581):434-438.
4. Banuelos SJ, et al. Regulation of skin and islet allograft survival in mice treated with costimulation blockade is mediated by different CD4+ cell subsets and different mechanisms. Transplantation. 2004;78(5):660-667.
5. Markees TG, et al. Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4(+) T cells, interferon-γ, and CTLA4. J Clin Invest. 1998; 101(11):2446-2455.
6. Mease P, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum. 2011;63(4):939-948.
7. Schiff M. Abatacept treatment for rheumatoid arthritis. Rheumatology (Oxford). 2011;50(3):437-449.
8. Vincenti F, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant. 2011;10(3):535-546.
9. Kreisel D, et al. Short-and long-term outcomes of 1000 adult lung transplant recipients at a single center. J Thorac Cardiovasc Surg. 2011;141(1):215-222.
10. Shah PD, McDyer JF. Viral infections in lung transplant recipients. Semin Respir Crit Care Med. 2010; 31(2):243-254.
11. Husain S, et al. Experience with immune monitoring in lung transplant recipients: correlation of low immune function with infection. Transplantation. 2009;87(12):1852-1857.
12. Adams AB, et al. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest. 2003;111(12):1887-1895.
13. Zhai Y, Meng L, Gao F, Busuttil RW, Kupiec-Weglinski JW. Allograft rejection by primed/memory CD8+ T cells is CD154 blockade resistant: therapeutic implications for sensitized transplant recipients. J Immunol. 2002;169(8):4667-4673.
14. Trambley J, et al. Asialo GM1(+) CD8(+) T cells play a critical role in costimulation blockade-resistant allograft rejection. J Clin Invest. 1999;104(12):1715-1722.
15. Schenk AD, Nozaki T, Rabant M, Valujskikh A, Fairchild RL. Donor-reactive CD8 memory T cells infiltrate cardiac allografts within 24-h posttransplant in naive recipients. Am J Transplant. 2008; 8(8):1652-1661.
16. Schenk AD, Gorbacheva V, Rabant M, Fairchild RL, Valujskikh A. Effector functions of donorreactive CD8 memory T cells are dependent on ICOS induced during division in cardiac grafts. Am J Transplant. 2009;9(1):64-73.
17. Koyama I, et al. Depletion of CD8 memory T cells for induction of tolerance of a previously transplanted kidney allograft. Am J Transplant. 2007; 7(5):1055-1061.
18. Donckier V, et al. Expansion of memory-type CD8+ T cells correlates with the failure of early immunosuppression withdrawal after cadaver liver transplantation using high-dose ATG induction and rapamycin. Transplantation. 2013;96(3):306-315.
19. Ascon M, et al. Renal ischemia-reperfusion leads to long term infiltration of activated and effector-memory T lymphocytes. Kidney Int. 2009;75(5):526-535.
20. Lo DJ, et al. Selective targeting of human alloresponsive CD8+ effector memory T cells based on CD2 expression. Am J Transplant. 2011;11(1):22-33.
21. Weaver TA, et al. Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates. Nat Med. 2009;15(7):746-749.
22. Dai H, Wan N, Zhang S, Moore Y, Wan F, Dai Z. Cutting edge: programmed death-1 defines CD8+CD122+ T cells as regulatory versus memory T cells. J Immunol. 2010;185(2):803-807.
23. Bahri R, Bollinger A, Bollinger T, Orinska Z, Bulfone-Paus S. Ectonucleotidase CD38 demarcates regulatory, memory-like CD8+ T cells with IFN-gamma-mediated suppressor activities. PLoS One. 2012;7(9):e45234.
24. Dubois A, et al. Regulation of Th2 responses and allergic inflammation through bystander activation of CD8+ T lymphocytes in early life. J Immunol. 2010;185(2):884-891.
25. Berry GJ, et al. The ISHLT working formulation for pathologic diagnosis of antibody-mediated rejection in heart transplantation: evolution and current status (2005-2011). J Heart Lung Transplant. 2011;30(6):601-611.
26. Maier S, et al. Inhibition of natural killer cells results in acceptance of cardiac allografts in CD28-/-mice. Nat Med. 2001;7(5):557-562.
27. McNerney ME, et al. Role of natural killer cell subsets in cardiac allograft rejection. Am J Transplant. 2006;6(3):505-513.
28. Nozaki T, et al. Antibody-mediated rejection of cardiac allografts in CCR5-deficient recipients. J Immunol. 2007;179(8):5238-5245.
29. Okazaki M, et al. Maintenance of airway epithelium in acutely rejected orthotopic vascularized mouse lung transplants. Am J Respir Cell Mol Biol. 2007;37(6):625-630.
30. Li W, et al. Lung transplant acceptance is facilitated by early events in the graft and is associated with lymphoid neogenesis. Mucosal Immunol. 2012; 5(5):544-554.
31. Gelman AE, et al. CD4+ T lymphocytes are not necessary for the acute rejection of vascularized mouse lung transplants. J Immunol. 2008;180(7):4754-4762.
32. Yousem SA, et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. J Heart Lung Transplant. 1996;15(1 pt 1):1-15.
33. Yamamoto S, et al. Cutting edge: Pseudomonas aeruginosa abolishes established lung transplant tolerance by stimulating B7 expression on neutrophils. J Immunol. 2012;189(9):4221-4225.
34. Rigby MR, Trexler AM, Pearson TC, Larsen CP. CD28/CD154 blockade prevents autoimmune diabetes by inducing nondeletional tolerance after effector t-cell inhibition and regulatory T-cell expansion. Diabetes. 2008;57(10):2672-2683.
35. Waldmann H, Cobbold S. Regulating the immune response to transplants. a role for CD4+ regulatory cells? Immunity. 2001;14(4):399-406.
36. Lee I, Wang L, Wells AD, Dorf ME, Ozkaynak E, Hancock WW. Recruitment of Foxp3+ T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor. J Exp Med. 2005; 201(7):1037-1044.
37. Iwakoshi NN, Mordes JP, Markees TG, Phillips NE, Rossini AA, Greiner DL. Treatment of allograft recipients with donor-specific transfusion and anti-CD154 antibody leads to deletion of alloreactive CD8+ T cells and prolonged graft survival in a CTLA4-dependent manner. J Immunol. 2000;164(1):512-521.
38. Walsh PT, Taylor DK, Turka LA. Tregs and transplantation tolerance. J Clin Invest. 2004;114(10):1398-1403.
39. Redfield RR, et al. Essential role for B cells in transplantation tolerance. Curr Opin Immunol. 2011; 23(5):685-691.
40. Okazaki M, et al. A mouse model of orthotopic vascularized aerated lung transplantation. Am J Transplant. 2007;7(6):1672-1679.
41. Habicht A, Najafian N, Yagita H, Sayegh MH, Clarkson MR. New insights in CD28-independent allograft rejection. Am J Transplant. 2007;7(8):1917-1926.
42. Xystrakis E, et al. Identification of a novel natural regulatory CD8 T-cell subset and analysis of its mechanism of regulation. Blood. 2004;104(10):3294-3301.
43. Lerret NM, Houlihan JL, Kheradmand T, Pothoven KL, Zhang ZJ, Luo X. Donor-specific CD8+ Foxp3+ T cells protect skin allografts and facilitate induction of conventional CD4+ Foxp3+ regulatory T cells. Am J Transplant. 2012;12(9):2335-2347.
44. Correale J, Villa A. Role of CD8+ CD25+ Foxp3+ regulatory T cells in multiple sclerosis. Ann Neurol. 2010;67(5):625-638.
45. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401(6754):708-712.
46. Ford ML, Kirk AD, Larsen CP. Donor-reactive T-cell stimulation history and precursor frequency: barriers to tolerance induction. Transplantation. 2009;87(9 suppl):S69-S74.
47. Bingaman AW, Farber DL. Memory T cells in transplantation: generation, function, and potential role in rejection. Am J Transplant. 2004;4(6):846-852.
48. Wan N, Dai H, Wang T, Moore Y, Zheng XX, Dai Z. Bystander central memory but not effector memory CD8+ T cells suppress allograft rejection. J Immunol. 2008;180(1):113-121.
49. Ely KH, Cookenham T, Roberts AD, Woodland DL. Memory T cell populations in the lung airways are maintained by continual recruitment. J Immunol. 2006;176(1):537-543.
50. Weninger W, Crowley MA, Manjunath N, von Andrian UH. Migratory properties of naive, effector, and memory CD8(+) T cells. J Exp Med. 2001; 194(7):953-966.
51. Ophir E, et al. Murine anti-third-party central-memory CD8(+) T cells promote hematopoietic chimerism under mild conditioning: lymph-node sequestration and deletion of anti-donor T cells. Blood. 2012;121(7):1220-1228.
52. Cobbold SP, et al. Infectious tolerance via the consumption of essential amino acids and mTOR signaling. Proc Natl Acad Sci U S A. 2009; 106(29):12055-12060.
53. Geller DA, et al. Cytokines, endotoxin, and glucocorticoids regulate the expression of inducible nitric oxide synthase in hepatocytes. Proc Natl Acad Sci U S A. 1993;90(2):522-526.
54. Purushothaman D, Marcel N, Garg M, Venkataraman R, Sarin A. Apoptotic programs are determined during lineage commitment of CD4+ T effectors: selective regulation of T effector-memory apoptosis by inducible nitric oxide synthase. J Immunol. 2013;190(1):97-105.
55. Gelman AE, et al. CCR2 regulates monocyte recruitment as well as CD4 T1 allorecognition after lung transplantation. Am J Transplant. 2010; 10(5):1189-1199.
56. Rogers NJ, Lechler RI. Allorecognition. Am J Transplant. 2001;1(2):97-102.
57. Friedman RS, Jacobelli J, Krummel MF. Surface-bound chemokines capture and prime T cells for synapse formation. Nat Immunol. 2006;7(10):1101-1108.
58. Kreisel D, et al. In vivo two-photon imaging reveals monocyte-dependent neutrophil extravasation during pulmonary inflammation. Proc Natl Acad Sci U S A. 2010;107(42):18073-18078.
59. Vincenti F, et al. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant. 2012;12(1):210-217.
60. Lo DJ, et al. Belatacept and sirolimus prolong nonhuman primate renal allograft survival without a requirement for memory T cell depletion. Am J Transplant. 2013;13(2):320-328.
61. Nadazdin O, et al. Host alloreactive memory T cells influence tolerance to kidney allografts in nonhuman primates. Sci Transl Med. 2011;3(86):86ra51.
62. Padiyar A, Augustine JJ, Hricik DE. Induction antibody therapy in kidney transplantation. Am J Kidney Dis. 2009;54(5):935-944.
63. Mackey MF, Barth RJ, Barth RJ Jr, Noelle RJ. The role of CD40/CD154 interactions in the priming, differentiation, and effector function of helper and cytotoxic T cells. J Leukoc Biol. 1998;63(4):418-428.
64. Moyron-Quiroz JE, et al. Persistence and responsiveness of immunologic memory in the absence of secondary lymphoid organs. Immunity. 2006; 25(4):643-654.
65. Moyron-Quiroz JE, et al. Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity. Nat Med. 2004;10(9):927-934.
66. Gelman AE, et al. Cutting edge: Acute lung allograft rejection is independent of secondary lymphoid organs. J Immunol. 2009;182(7):3969-3973.
67. Kreisel D, et al. Emergency granulopoiesis promotes neutrophil-dendritic cell encounters that prevent mouse lung allograft acceptance. Blood. 2011;118(23):6172-6182.
68. Barker CF, Billingham RE. The role of afferent lymphatics in the rejection of skin homografts. J Exp Med. 1968;128(1):197-221.
69. Zhang N, et al. Regulatory T cells sequentially migrate from inflamed tissues to draining lymph nodes to suppress the alloimmune response. Immunity. 2009;30(3):458-469.
70. Lakkis FG, Arakelov A, Konieczny BT, Inoue Y. Immunologic 'ignorance' of vascularized organ transplants in the absence of secondary lymphoid tissue. Nat Med. 2000;6(6):686-688.
71. Walch JM, et al. Cognate antigen directs CD8+ T cell migration to vascularized transplants. J Clin Invest. 2013;123(6):2663-2671.
72. Mikhak Z, Strassner JP, Luster AD. Lung dendritic cells imprint T cell lung homing and promote lung immunity through the chemokine receptor CCR4. J Exp Med. 2013;210(9):1855-1869.
73. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155(3):1151-1164.
74. Suzuki M, et al. CD8+CD45RA+CCR7+FOXP3+ T cells with immunosuppressive properties: a novel subset of inducible human regulatory T cells. J Immunol. 2012;189(5):2118-2130.
75. Guillonneau C, et al. CD40Ig treatment results in allograft acceptance mediated by CD8CD45RC T cells, IFN-γ, and indoleamine 2,3-dioxygenase. J Clin Invest. 2007;117(4):1096-1106.
76. Myers L, Croft M, Kwon BS, Mittler RS, Vella AT. Peptide-specific CD8 T regulatory cells use IFN-γ to elaborate TGF-β-based suppression. J Immunol. 2005;174(12):7625-7632.
77. Beckmann JH, et al. Prolongation of allograft survival in ccr7-deficient mice. Transplantation. 2004;77(12):1809-1814.
78. Ziegler E, et al. CCL19-IgG prevents allograft rejection by impairment of immune cell trafficking. J Am Soc Nephrol. 2006;17(9):2521-2532.
79. Liu X, et al. Tolerance induction towards cardiac allografts under costimulation blockade is impaired in CCR7-deficient animals but can be restored by adoptive transfer of syngeneic plasmacytoid dendritic cells. Eur J Immunol. 2011;41(3):611-623.
80. Gregson AL, et al. Protection against bronchiolitis obliterans syndrome is associated with allograft CCR7+ CD45RA-T regulatory cells. PLoS One. 2010; 5(6):e11354.
81. Kaiser A, Donnadieu E, Abastado JP, Trautmann A, Nardin A. CC chemokine ligand 19 secreted by mature dendritic cells increases naive T cell scanning behavior and their response to rare cognate antigen. J Immunol. 2005;175(4):2349-2356.
82. Ngo VN, Tang HL, Cyster JG. Epstein-Barr virus-induced molecule 1 ligand chemokine is expressed by dendritic cells in lymphoid tissues and strongly attracts naive T cells and activated B cells. J Exp Med. 1998;188(1):181-191.
83. Kuwabara T, et al. CCR7 ligands are required for development of experimental autoimmune encephalomyelitis through generating IL-23-dependent Th17 cells. J Immunol. 2009;183(4):2513-2521.
84. Noor S, et al. CCR7-dependent immunity during acute Toxoplasma gondii infection. Infect Immun. 2010;78(5):2257-2263.
85. Konieczny BT, et al. IFN-γ is critical for long-term allograft survival induced by blocking the CD28 and CD40 ligand T cell costimulation pathways. J Immunol. 1998;160(5):2059-2064.
86. Yuan X, et al. A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy. J Exp Med. 2008;205(13):3133-3144.
87. Sis B, Famulski KS, Allanach KL, Zhu LF, Halloran PF. IFN-gamma prevents early perforin-granzymemediated destruction of kidney allografts by inducing donor class I products in the kidney. Am J Transplant. 2007;7(10):2301-2310.
88. Sheridan BS, Lefrancois L. Regional and mucosal memory T cells. Nat Immunol. 2011;12(6):485-491.
89. Sathaliyawala T, et al. Distribution and compartmentalization of human circulating and tissue-resident memory T cell subsets. Immunity. 2013;38(1):187-197.
90. Teijaro JR, Turner D, Pham Q, Wherry EJ, Lefrancois L, Farber DL. Cutting edge: tissue-retentive lung memory CD4 T cells mediate optimal protection to respiratory virus infection. J Immunol. 2011; 187(11):5510-5514.
91. Lentsch AB, Ward PA. Regulation of experimental lung inflammation. Respir Physiol. 2001;128(1):17-22.
92. Zeidler PC, Millecchia LM, Castranova V. Role of inducible nitric oxide synthase-derived nitric oxide in lipopolysaccharide plus interferon-gamma- induced pulmonary inflammation. Toxicol Appl Pharmacol. 2004;195(1):45-54.
93. Kobayashi H, et al. Antiinflammatory properties of inducible nitric oxide synthase in acute hyperoxic lung injury. Am J Respir Cell Mol Biol. 2001; 24(4):390-397.
94. Masopust D, Ha SJ, Vezys V, Ahmed R. Stimulation history dictates memory CD8 T cell phenotype: implications for prime-boost vaccination. J Immunol. 2006;177(2):831-839.
95. Kaech SM, Cui W. Transcriptional control of effector and memory CD8+ T cell differentiation. Nat Rev Immunol. 2012;12(11):749-761.
96. He X, et al. Mycophenolic acid-mediated suppression of human CD4+ T cells: more than mere guanine nucleotide deprivation. Am J Transplant. 2011; 11(3):439-449.
97. Dusting GJ, Akita K, Hickey H, Smith M, Gurevich V. Cyclosporin A and tacrolimus (FK506) suppress expression of inducible nitric oxide synthase in vitro by different mechanisms. Br J Pharmacol. 1999;128(2):337-344.
98. Cypel M, et al. Functional repair of human donor lungs by IL-10 gene therapy. Sci Transl Med. 2009; 1(4):4ra9.